Results 91 to 100 of about 15,436 (169)

Clinical Impact of Diagnostic Delay by Red Flags Assessment in Transthyretin Amyloid Cardiomyopathy. [PDF]

JACC Adv
Iseppi M, Moretti M, Capovilla TM, Zaro E, Barbati G, Bonvicini E, Morat F, Marini M, Bonmassari R, Sinagra G, Merlo M, Porcari A.   +11 more
europepmc   +1 more source

Transthyretin Amyloid Cardiomyopathy in Women: Epidemiology, Diagnostic Delay, and Clinical Implications. [PDF]

Cardiol Ther
Madhani A, Ancha B, Alexander KM, Vaishnav J.   +3 more
europepmc   +1 more source

Pathology-Based Validation of Quantitative SPECT/CT in Patients With Suspected Transthyretin Amyloid Cardiomyopathy. [PDF]

Circ Cardiovasc Imaging
Tersalvi G, Bois MC, Scott CG, Carey P, Garmany A, Davies DR, Hoffman AC, Zhang J, Hruska CB, Jouni H, Rodriguez-Porcel MG, Askew JW, Bois JP, Young KA, Anavekar NS, Chang IC, Grogan M, Dispenzieri A, Maleszewski JJ, Homb AC, Redfield MM, Chareonthaitawee P, Johnson GB, AbouEzzeddine OF.   +23 more
europepmc   +1 more source

Expert Consensus and Clinical Pathway Recommendations for Transthyretin Amyloid Cardiomyopathy in Malaysia. [PDF]

Int J Heart Fail
Yusoff MR, Raja Shariff REF, Tee CK, Lee KW, Mohd Amin NH, Chen LS, Erng T, Arumugam K, Yaser SN, Tan JTC, Ganapaty S, Omar R, Abdul Rahman T, Ngu LH, Low SC, Che Rahim NS, Oon YY.   +16 more
europepmc   +1 more source

Real-World Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy: A Pharmacovigilance Study. [PDF]

J Cardiovasc Dev Dis
Chai GW, Phi Q, Delgado DH.
europepmc   +1 more source

Machine Learning-Driven Risk Prediction Model in Transthyretin Amyloid Cardiomyopathy.

JAMA Cardiol
Baj G, Ciocca N, Mohammadi Kazaj P, Ma X, Studer Bruengger AA, Stämpfli SF, Ehl NF, Hugelshofer S, Pfister O, Lehmann J, Ryffel C, Hunziker L, Poledniczek M, Kammerlander A, Siontis GCM, Windecker S, Hundertmark MJ, Nitsche C, Shiri I, Gräni C.   +19 more
europepmc   +1 more source

Disease-Modifying Therapies for Transthyretin Amyloid Cardiomyopathy: Current Evidence and Emerging Strategies. [PDF]

J Clin Med Res
Kachhadia MP, Gautam A, Meadows S, Kotadiya SR, Aryal R, Ilyas H, Shaikh JD, Gill G, Shah S, Patel J, Sanghvi HA.   +10 more
europepmc   +1 more source

Prognostic Thresholds of Tricuspid Regurgitation in Transthyretin Amyloid Cardiomyopathy.

JAMA Cardiol
Hauptmann L, Schwarting SK, Tomasoni D, Zanders L, Kronberger C, Koschatko S, Autherith M, Singer K, Jantsch C, Heitzinger G, Demirel C, Duca F, Kammerlander A, Bordignon L, Guidi Colombi G, Schwegel N, Serenelli M, Porcari A, Kieviet LC, Verheyen N, Oerlemans MIFJ, Papathanasiou M, Hengstenberg C, Sinagra G, Hausleiter J, Adamo M, Bartko PE, Nitsche C.   +27 more
europepmc   +1 more source

Monitoring the Electrical Phenotype of Transthyretin Amyloid Cardiomyopathy in the Era of Disease-Modifying Therapy. [PDF]

Circ Rep
Yonezu K, Kondo H, Takahashi N.
europepmc   +1 more source

A trial emulation study indirectly comparing tafamidis and acoramidis in transthyretin amyloid cardiomyopathy: the ReplicATTR study. [PDF]

J Comp Eff Res
Debonnaire P, Zwetsloot PP, Pfister R, Llàcer P, Cipriani A, Milani P, Bonderman D, Ohlmeier C, Evers T, Wyss R, Patorno E, Doshi R, Beisel J, Coleman CI, Aguiar C, Ripoll-Vera T.   +15 more
europepmc   +1 more source